Overview of Neutralizing Antibodies and Their Potential in COVID-19
Open Access
Abstract
The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd immunity against SARS-CoV-2, vaccine efficacy, and humoral protective response longevity, as well as supporting donor selection criteria for convalescent plasma therapy. In the current manuscript, we review the essential concepts of NAbs, examining their concept, mechanisms of action, production, and the techniques used for their detection; as well as presenting an overview of the clinical use of antibodies in COVID-19.Keywords
This publication has 178 references indexed in Scilit:
- Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120Proceedings of the National Academy of Sciences, 2012
- Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutantsJournal of Experimental Medicine, 2011
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Nature, 2011
- The Antibody Response against HIV-1Cold Spring Harbor Perspectives in Medicine, 2011
- The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 + T Cell Decline and High Viral Load during Acute InfectionJournal of Virology, 2011
- Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infectionRetrovirology, 2011
- Mechanisms of viral entry: sneaking in the front doorProtoplasma, 2010
- Rapid cloning of high-affinity human monoclonal antibodies against influenza virusNature, 2008
- Mechanism and Regulation of Class Switch RecombinationAnnual Review of Immunology, 2008
- Different mechanisms of antibody-mediated neutralization of parvoviruses revealed using the Fab fragments of monoclonal antibodiesVirology, 2007